Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727061 · ClinicalTrials.gov registry record · Phase 1
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03727061 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT03727061, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects of interstitial photodynamic therapy (I-PDT) in treating patients with head and neck cancer that has spread to other parts of the body or that has come back. Interstitial photodynamic therapy uses a light-sensitive drug called porfimer sodium. This drug is activated by laser light delivered through special fibers into the tumor. In this study the doctors will evaluate the safety of I-PDT and determine the potentially effective light setting in this treatment.
Interventions
- BIOLOGICAL Nivolumab
- OTHER Quality of Life Assessment
- DRUG Porfimer Sodium
- PROCEDURE Interstitial Illumination Photodynamic Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-07-10 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03727061
The ClinicalTrials.gov registry entry for NCT03727061 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT03727061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03727061 about?
NCT03727061 is a clinical study titled "Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer". This phase I trial studies the side effects of interstitial photodynamic therapy (I-PDT) in treating patients with head and neck cancer that has spread to other parts of the body or that has come back. Interstitial photodynamic therapy uses a light-sensitive drug called porfimer sodium. This drug is...
What is the current status of trial NCT03727061?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-07-10. Estimated completion is 2024-10-22.
What interventions are being tested in trial NCT03727061?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Quality of Life Assessment (OTHER), Porfimer Sodium (DRUG), Interstitial Illumination Photodynamic Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT03727061?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.